Skip to search formSkip to main contentSkip to account menu

Anti-TIM-3 Monoclonal Antibody TSR-022

Known as: Anti-TIM3 Checkpoint Inhibitor TSR-022, Anti-TIM3 Monoclonal Antibody TSR-022, TSR-022 
A monoclonal antibody against the inhibitory T-cell receptor, T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 3242: Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 reinvigorates ovarian cancer-infiltrating T cells by increasing T cell polyfunctionality and effector function
Co-expression of immune checkpoint receptors (ICRs) PD-1, TIM-3, and LAG-3 characterizes chronically activated and exhausted… 
2016
2016
Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
2016
2016
Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma
Programmed cell death protein 1 (PD-1) and T-cell immunoglobulin domain and mucin domain containing molecule 3 (TIM-3) are… 
2013
2013
Antarctic circumpolar current from satellite gravimetric models ITG-GRACE2010, GOCE-TIM3 and satellite altimetry
2005
2005
Hemofil-M study
Previous results of our randomized study, comparing the effects of the replacement therapy using an intermediate-purity factor… 
1997
1997
No effect of a new second‐generation B‐domain‐deleted recombinant product on lymphocyte transformation in vitro: a study of plasma‐derived and recombinant products
Immunomodulatory effects of various factor VIII and factor IX clotting factor concentrates (CFCs) and of albumin were evaluated… 
Highly Cited
1988
Highly Cited
1988
Biochemical and in vivo properties of commercial virus‐inactivated factor VIII concentrates
The following commercial virus‐inactivated factor VIII concentrates were studied in vitro: AHF‐Kabi and Octonativ, KabiVitrum… 
Highly Cited
1986
Highly Cited
1986
Pharmacokinetics of a new heat-treated concentrate of factor VIII estimated by model-independent methods.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)